Mild to moderate hyperhomocysteinaemia in cardiovascular disease.
Elevated serum levels of homocysteine, a sulphur-containing amino acid, are increasingly recognized as an independent risk factor for atherosclerotic and thrombotic vascular disease. Presence of a thermolabile variant of methylenetetrahydrofolatereductase and an inadequate folate status are the most common causes of hyperhomocysteinaemia. Homocysteine damages the vessel wall mainly through generation of oxygen radicals and creates a prothrombotic environment. In the majority of cases, normalization of homocysteine levels can be achieved with administration of vitamins of the B-group. The effect of this treatment on cardiovascular outcome, however, remains undefined.